Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Recommendation of “Hold” from Analysts

Posted by Brenda Bartman on Sep 12th, 2026

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) have received a consensus recommendation of “Hold” from the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $29.15.

Several brokerages have recently commented on CAPR. Oppenheimer upgraded shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, August 25th. JonesTrading lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. LADENBURG THALM/SH SH cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Finally, Piper Sandler upgraded Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a report on Tuesday, September 1st.

Read Our Latest Report on CAPR

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 25,000 shares of company stock worth $759,158. Corporate insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its position in Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 2,786 shares during the last quarter. ACT Capital Management LLC acquired a new stake in Capricor Therapeutics in the 4th quarter valued at approximately $43,000. KBC Group NV bought a new position in Capricor Therapeutics in the 1st quarter worth approximately $44,000. Tower Research Capital LLC TRC increased its position in Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC bought a new stake in Capricor Therapeutics in the 3rd quarter valued at $92,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR opened at $8.37 on Friday. The stock’s 50 day moving average price is $11.05 and its 200 day moving average price is $23.21. Capricor Therapeutics has a 52 week low of $2.96 and a 52 week high of $40.37. The company has a market capitalization of $486.63 million, a P/E ratio of -3.42 and a beta of 0.72.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). As a group, sell-side analysts forecast that Capricor Therapeutics will post -1.71 earnings per share for the current fiscal year.

Key Stories Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

Positive Sentiment: No new positive corporate or clinical development was reported in the provided articles that would offset the legal and regulatory concerns.
Neutral Sentiment: Multiple law firms reminded investors that September 28, 2026 is the deadline to seek appointment as lead plaintiff in a proposed class action covering investors who acquired Capricor securities from December 17, 2025, through July 26, 2026. The notices are largely duplicative and do not represent separate lawsuits or new operational developments. Kaplan Fox class action notice
Negative Sentiment: The litigation alleges that Capricor failed to disclose that it changed the prespecified statistical analysis plan for its Phase 3 HOPE-3 trial without FDA agreement, leaving portions of the results characterized by the agency as “post-hoc and exploratory.” These allegations raise risks involving potential damages, legal expenses, management distraction, and reputational damage. Capricor shareholder alert
Negative Sentiment: The FDA’s decision to extend its review of deramiocel’s BLA adds uncertainty around the timing and potential outcome of approval for Capricor’s key product candidate. The extended review is the central regulatory issue cited in the investor alerts and likely contributes to continued volatility. Hagens Berman FDA review extension alert
Negative Sentiment: The legal overhang is particularly significant for a development-stage biotechnology company with continuing losses. CAPR remains well below its 50-day and 200-day moving averages, indicating sustained bearish momentum, although the supplied short-interest data appears inconsistent and provides no reliable additional signal.

Capricor Therapeutics Company Profile

(Get Free Report)

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.